Skip to main content
Premium Trial:

Request an Annual Quote

Italian Diagnostic Shop Distributing Transgenomic's Mutation Detection System in Europe

NEW YORK (GenomeWeb News) – Italian firm A. Menarini Diagnostics will exclusively distribute Transgenomic's Surveyor Scan and Wave Micro-capillary electrophoresis (MCE) mutation detection system throughout Europe as part of a deal announced today.

Under the terms of the deal, Menarini, based in Florence, Italy, will make the Transgenomic technology available to the more than 2,000 pathologists in its European network. Financial details were not disclosed.

The Surveyor technology uses "PCR amplification reaction and hybridization to form mispaired DNA molecules where there are mutations," Transgenomic said in a statement. It added that the Surveyor Scan KRAS kit has performed equivalently to allele-specific methods, such as Scorpion amplification refractory mutation system and pyrosequencing.

During the past two years, Transgenomic has marketed the kits for cancer genes such as KRAS, BRAF, and PI-3 kinase for its Wave systems. Earlier this year, the firm began developing the technology for Wave MCE technology, and today's agreement "will accelerate the adoption of our Surveyor Scan Mutation Detection kits and Wave MCE platform among this key" market of pathologists, Transgenomic CEO Craig Tuttle said.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.